Recently, regenerative medicine has emerged as an important field, showing therapeutic potential of adult stem cells in medicine. As part of regenerative medicine, tissue engineering can be used to generate tissues in vitro to repair damaged tissues. Development of successful engineered tissues is dependent on choosing the ideal cell source for the tissue, and adult stem cells have been shown as a highly favorable candidate. Stem cells have some characteristics that distinguish them from other cell types: they have the potential for self-renewal, they can be induced to differentiate in different cell types, and they can be implanted in healthy and damaged tissues. Mesenchymal stem cells from different tissues (i.e. bone marrow, adipose tissue, umbilical cord blood, etc.) are promising cell types in regenerative medicine, due to their ability to differentiate into several cell lineages and their immunomodulatory properties. On the other hand, blood-derived cells are a very useful for the studying the immune response, autoimmune diseases, and some forms of cancer.
ARP has partnered with Cellider Biotech, based in Zaragoza, Spain.
Cellider Biotech pursues to become a reference center in adult stem cell field, consisting of all products and services that can ease researcher and biomedical professional tasks, including primary cultures, stem cells from different animals and sources, extracellular matrix, and biomaterials. Advances in this area will help patients suffering pathology susceptible to be treated by cell therapy.
Thanks to the collaboration with research groups in regenerative medicine and tissue engineering, Cellider Biotech started as a spin-off of the Aragon Health Sciences Institute (IACS & ISS-Aragón).